Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arunan S. Vamadevan is active.

Publication


Featured researches published by Arunan S. Vamadevan.


Seminars in Immunology | 2009

Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders

Masayuki Fukata; Arunan S. Vamadevan; Maria T. Abreu

Toll-like receptors (TLRs) and Nod-like receptors (NLRs) are two major forms of innate immune sensors, which provide immediate responses against pathogenic invasion or tissue injury. Activation of these sensors induces the recruitment of innate immune cells such as macrophages and neutrophils, initiates tissue repair processes, and results in adaptive immune activation. Abnormalities in any of these innate sensor-mediated processes may cause excessive inflammation due to either hyper responsive innate immune signaling or sustained compensatory adaptive immune activation. Recent gene association studies appear to reveal strong associations of NLR gene mutations and development of several idiopathic inflammatory disorders. In contrast, TLR polymorphisms are less often associated with inflammatory disorders. Nevertheless, TLRs are up-regulated in the affected tissue of most inflammatory disorders, suggesting TLR signaling is involved in the pathogenesis of chronic and/or idiopathic inflammatory disorders. NLR signaling results in the formation of a molecular scaffold complex (termed an inflammasome) and orchestrates with TLRs to induce IL-1beta and IL-18, both of which are important mediators in the majority of inflammatory disorders. Therefore, understanding the roles of TLRs and NLRs in the pathogenesis of chronic and idiopathic inflammatory disorders may provide novel targets for the prevention and/or treatment of many common and uncommon diseases involving inflammation.


Journal of Immunology | 2008

The myeloid differentiation factor 88 (MyD88) is required for CD4 + T cell effector function in a murine model of inflammatory bowel disease

Masayuki Fukata; Keith J. Breglio; Anli Chen; Arunan S. Vamadevan; Tyralee Goo; David S. Hsu; Daisy E. Conduah; Ruliang Xu; Maria T. Abreu

Abnormal T cell responses to commensal bacteria are involved in the pathogenesis of inflammatory bowel disease. MyD88 is an essential signal transducer for TLRs in response to the microflora. We hypothesized that TLR signaling via MyD88 was important for effector T cell responses in the intestine. TLR expression on murine T cells was examined by flow cytometry. CD4+CD45Rbhigh T cells and/or CD4+CD45RblowCD25+ regulatory T cells were isolated and adoptively transferred to RAG1−/− mice. Colitis was assessed by changes in body weight and histology score. Cytokine production was assessed by ELISA. In vitro proliferation of T cells was assessed by [3H]thymidine assay. In vivo proliferation of T cells was assessed by BrdU and CFSE labeling. CD4+CD45Rbhigh T cells expressed TLR2, TLR4, TLR9, and TLR3, and TLR ligands could act as costimulatory molecules. MyD88−/− CD4+ T cells showed decreased proliferation compared with WT CD4+ T cells both in vivo and in vitro. CD4+CD45Rbhigh T cells from MyD88−/− mice did not induce wasting disease when transferred into RAG1−/− recipients. Lamina propria CD4+ T cell expression of IL-2 and IL-17 and colonic expression of IL-6 and IL-23 were significantly lower in mice receiving MyD88−/− cells than mice receiving WT cells. In vitro, MyD88−/− T cells were blunted in their ability to secrete IL-17 but not IFN-γ. Absence of MyD88 in CD4+CD45Rbhigh cells results in defective T cell function, especially Th17 differentiation. These results suggest a role for TLR signaling by T cells in the development of inflammatory bowel disease.


Inflammatory Bowel Diseases | 2011

Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis

Masayuki Fukata; Limin Shang; Rebeca Santaolalla; John Sotolongo; Cristhine Pastorini; Cecilia Espana; Ryan Ungaro; Noam Harpaz; Harry S. Cooper; Greg Elson; Marie Kosco-Vilbois; Julia Zaias; Maria T. Perez; Lloyd Mayer; Arunan S. Vamadevan; Sergio A. Lira; Maria T. Abreu

Background: Chronic intestinal inflammation culminates in cancer and a link to Toll‐like receptor‐4 (TLR4) has been suggested by our observation that TLR4 deficiency prevents colitis‐associated neoplasia. In the current study we address the effect of the aberrant activation of epithelial TLR4 on induction of colitis and colitis‐associated tumor development. We take a translational approach to address the consequences of increased TLR signaling in the intestinal mucosa. Methods: Mice transgenic for a constitutively active TLR4 under the intestine‐specific villin promoter (villin‐TLR4 mice) were treated with dextran sodium sulfate (DSS) for acute colitis and azoxymethane (AOM)‐DSS TLR4 expression was analyzed by immunohistochemistry in colonic tissue from patients with ulcerative colitis (UC) and UC‐associated cancer. The effect of an antagonist TLR4 antibody (Ab) was tested in prevention of colitis‐associated neoplasia in the AOM‐DSS model. Results: Villin‐TLR4 mice were highly susceptible to both acute colitis and colitis‐associated neoplasia. Villin‐TLR4 mice had increased epithelial expression of COX‐2 and mucosal PGE2 production at baseline. Increased severity of colitis in villin‐TLR4 mice was characterized by enhanced expression of inflammatory mediators and increased neutrophilic infiltration. In human UC samples, TLR4 expression was upregulated in almost all colitis‐associated cancer and progressively increased with grade of dysplasia. As a proof of principle, a TLR4/MD‐2 antagonist antibody inhibited colitis‐associated neoplasia in the mouse model. Conclusions: Our results show that regulation of TLRs can affect the outcome of both acute colitis and its consequences, cancer. Targeting TLR4 and other TLRs may ultimately play a role in prevention or treatment of colitis‐associated cancer. (Inflamm Bowel Dis 2010;)


Innate Immunity | 2010

Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis.

Arunan S. Vamadevan; Masayuki Fukata; Elizabeth T. Arnold; Lisa S. Thomas; David Hsu; Maria T. Abreu

The intestinal epithelium maintains a state of controlled inflammation despite continuous contact with Gram-negative commensal bacteria and lipopolysaccharide (LPS) on its luminal surface. Recognition of LPS by the Toll-like receptor (TLR) 4/MD-2 complex results in pro-inflammatory gene expression and cytokine secretion in intestinal epithelial cells (IECs). We have shown that IECs express low levels of MD-2 and TLR4 and are poorly responsive to LPS. In this study, we did a comprehensive analysis to understand the immune-mediated and epigenetic mechanisms by which IECs down-regulate MD-2 expression. Expression of MD-2 and TLR4 mRNA was examined in human inflammatory bowel disease and intestinal epithelial cell lines (T84, HT-29, Caco-2). Nuclear factor-κB transcriptional activation was used as a measure of LPS responsiveness. Intestinal epithelial cells in patients with inflammatory bowel disease exhibited increased expression of MD-2 and TLR4 mRNA. Lipopolysaccharide responsiveness in IECs was polarized to the basolateral membrane. Bisulfite sequencing of the MD-2 promoter demonstrated methylation of CpG dinucleotides. Inhibition of methylation by 5-azacytidine and histone de-actylation by trichostatin A, two forms of epigenetic silencing, resulted in increased mRNA expression of MD-2 in IECs. These results demonstrate various molecular mechanisms by which IECs down-regulate MD-2 and, thereby, protect against dysregulated inflammation to commensal bacteria in the intestinal lumen.


Gastroenterology | 2010

M1776 Toll-Like Receptor 4 (TLR4) is a Target of Wnt/β-Catenin Signaling in Intestinal Epithelial Cells (IEC): Implications for Sporadic Colon Cancer

Arunan S. Vamadevan; Masayuki Fukata; John Sotolongo; Cecilia Espana; Rebeca Santaolalla; Lory Hayes; Maria T. Abreu

whether colonic tissue-specific factors are responsible for re-educating DC into a gut-like phenotype. To address this issue we cultured human colonic biopsies from healthy controls and collected supernatants (SN) to condition human blood DC for 24 hours. RESULTS: Conditioning DC with SN generated In Vitro a human gut-like DC phenotype, characterized by a higher proportion of cells expressing the CCR9 (p=0.0017, n=11), β7 (p=0.0328, n=13) and CD103 (p=0.0354, n=10) gut-homingmarkers compared with their basal counterparts. A tolerogenic phenotype was also induced, characterized by reduced surface expression of the co-stimulatory markers CD40 (p=0.0297, n=9) and CD83 (p=0.0315, n=8), and also of TLR2 (p=0.0029, n=13) and TLR4 (p=0.0372, n=11). In addition, a regulatory intracellular DC cytokine profile was induced with reduced IL-12 and increased IL-10 production (n= 3). Furthermore, SN-conditioned DC demonstrated enhanced phagocytic properties (n=3), compared with those in basal conditions. These data demonstrate that human blood DC can be modulated to express the phenotype and function of human gut DC. Moreover, SNconditioned DC were less effective in stimulating proliferation of allogeneic T-cells, which subsequently expressed an increased gut/skin homing profile (n=3). CONCLUSION: We have demonstrated the relevance of the local tissue microenvironment in modulating DC since conditioning blood DC with colonic biopsy SN -through a mechanism in which vitamin A was revealed as essential but not sufficienthave the capacity to condition DC into gutlike DC with unique properties rendering them crucial for oral tolerance. Identifying all the molecules related to the generation of the tolerogenic gut-like DC would provide us with new targets for immunomodulation in patients suffering from IBD, where the functionality of gut-DC is altered leading to a lack of oral tolerance against the commensal microbiota.


Gastroenterology | 2007

Toll-Like Receptor-4 Promotes the Development of Colitis-Associated Colorectal Tumors

Masayuki Fukata; Anli Chen; Arunan S. Vamadevan; Jason P. Cohen; Keith J. Breglio; Suneeta Krishnareddy; David Hsu; Ruliang Xu; Noam Harpaz; Andrew J. Dannenberg; Kotha Subbaramaiah; Harry S. Cooper; Steven H. Itzkowitz; Maria T. Abreu


Gastroenterology | 2006

Cox-2 Is Regulated by Toll-Like Receptor-4 (TLR4) Signaling: Role in Proliferation and Apoptosis in the Intestine

Masayuki Fukata; Anli Chen; Arielle Klepper; Suneeta Krishnareddy; Arunan S. Vamadevan; Lisa S. Thomas; Ruliang Xu; Hiroyasu Inoue; Moshe Arditi; Andrew J. Dannenberg; Maria T. Abreu


Gastroenterology | 2006

Basic–alimentary tractCox-2 Is Regulated by Toll-Like Receptor-4 (TLR4) Signaling: Role in Proliferation and Apoptosis in the Intestine

Masayuki Fukata; Anli Chen; Arielle Klepper; Suneeta Krishnareddy; Arunan S. Vamadevan; Lisa S. Thomas; Ruliang Xu; Hiroyasu Inoue; Moshe Arditi; Andrew J. Dannenberg; Maria T. Abreu


Gastroenterology | 2009

586 Toll-Like Receptor 3 (TLR3) Signaling Improves Intestinal Mucosal Defense Against Pathogens

John Sotolongo; Andrea Echeverry; Cecilia Espana; Rebecca Adkins; Arunan S. Vamadevan; Lory Hayes; Julia Zaias; Masayuki Fukata


Gastroenterology | 2013

Su1214 Opiate Use in Inflammatory Bowel Disease (IBD): Impact on Biologic/Immune Modulator Utilization and Associated Outcomes

Arunan S. Vamadevan; Ariy Volfson; Sundas Khan; Lauren McCullagh; Meredith Akerman; Keith Sultan

Collaboration


Dive into the Arunan S. Vamadevan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anli Chen

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ruliang Xu

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lisa S. Thomas

Cedars-Sinai Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge